ASLAN Pharmaceuticals wins Red Herring Top 100 Asia Award

ASLAN currently has 3 drugs in clinical development, with the lead compound entering phase 2b for gastric cancer


ASLAN Pharmaceuticals has won the prestigious Red Herring Top 100 Asia Award 2013 which recongnizes the most innovative and promising private companies in the region. ASLAN was the only clinical stage life sciences company in Asia to receive the award this year.

"ASLAN set out to transform the way we develop drugs for life threatening disease, particularly those more prevalent in Asia. In three years we have built a rich portfolio of drugs in oncology and inflammation, each of which has the potential to be a major new medicine.This award recongnises the creative approach ASLAN's team has pioneered in Asia" express Dr Carl Firth, CEO.

"Choosing the companies with the strongest potential was by no means a small feat," said Alex Vieux, publisher and CEO of Red Herring. "After rigorous contemplation and discussion, we narrowed our list down from hundreds of candidates from across the Asia to the Top 100 winners. We believe ASLAN Pharmaceuticals embodies the vision, drive and innovation that define a successful entrepreneurial venture. ASLAN should be proud of its accomplishment, as the competition was the strongest it has ever seen" Mr Vieux added.

Red Herring's editorial staff evaluated the companies on both quantitative and qualitative criteria, such as financial performance, technology innovation, management quality, strategy, and market penetration

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email